



# A humanized minipig model for the toxicological testing of therapeutic recombinant antibodies

---

In the format provided by the authors and unedited

## **Contents**

**Supplementary Fig. 1** | V(D)J sequencing.

**Supplementary Fig. 2** | Sequence and structural mapping of the different interactions of PD-L1 epitope amino acid side-chains with atezolizumab paratope residues.

**Supplementary Table 1** | List of Ab compounds

**Supplementary Table 2** | List of primers.



VH3-23: ADSVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK N(D)N JH Cy

>p1 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DYYGSGSY DAFDWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL D3-9

>p2 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DRG FDYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p4 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK LY YFDWQGGTMVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p5 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCA ITGV DYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p6 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK APP FDIWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL

>p7 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCA N YWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p8 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK D YWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p9 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DGT C YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p10 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK ES YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p11 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAV AN YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p12 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DYYGSGSY YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL D3-9

>p14 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK SLD P WQGGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p15 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DFG DA FDIWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL

>p17 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK D FDYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p18 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK S YWYFDLWGRGT LVTVSS (2) AST KGPS VFPLAPSS KSTS GGTAAL

>p19 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK T DA FDIWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL

>p20 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK VYYGSGSY DA FDIWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL D3-9

>p22 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DLD YFDWQGGTMVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p24 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK ELT DA FDIWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL

>p25 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DG YFDWQGGTMVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p26 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK EY YFDWQGGTMVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p27 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAV LHYDH AFDWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL

>p28 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCA SWGY YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p29 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DA FDIWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL

>p30 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCA MWG YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p31 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DRGF DYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p32 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DPRDY YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p33 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCA IITGD YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p34 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK WGS FDYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p36 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DKVSNY YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p37 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK D FDIWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL

>p38 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK VLAGPPD YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p39 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK GGGSGSY DA FDIWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL D3-9

>p41 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DLGI YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p42 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DYGSGSY NWFDFWQGGTMVTVSS (5) AST KGPS VFPLAPSS KSTS GGTAAL D3-9

>p43 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DLTGV DYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p44 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK TGF FDYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p45 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DKVSNY YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p46 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK RLTDG YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p47 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK D YFDWQGGTMVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p48 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DY DYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p50 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DD DYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p596 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK DDRPWLWFGETS MDVWGQGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p1528 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCAK RQYSSSYKWFDP WQGGT LVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p1565 AD SVKGRETTISRDNKNTLYLQMNLSLRAEDTAVYCA RFSSESPDYF YGLDWWQGGTMVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

VH1-18: GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR N(D)N JH Cy

>p1 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR V YFDLWGRGT LVTVSS (2) AST KGPS VFPLAPSS KSTS GGTAAL

>p8 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR V YFDLWGRGT LVTVSS (2) AST KGPS VFPLAPSS KSTS GGTAAL

>p2 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR D DYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p10 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR D DYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p15 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR D DYWGRT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p3 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR AFDIWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL

>p14 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR AFDIWQGGTMVTVSS (3) AST KGPS VFPLAPSS KSTS GGTAAL

>p4 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCA S DYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p13 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCA S DYWGQGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p26 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR N WQGGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p30 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR DD YYYYYMDVWGKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p41 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR AGMGV WCKGT TTVTVSS (6) AST KGPS VFPLAPSS KSTS GGTAAL

>p52 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR DHWGL YFDLWGRGT LVTVSS (2) AST KGPS VFPLAPSS KSTS GGTAAL

>p113 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR DHWGL YFDLWGRGT LVTVSS (2) AST KGPS VFPLAPSS KSTS GGTAAL

>p60 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR GY YFDWQGGTMVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p83 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCAR GY YFDWGRGT LVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL


>p67 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCA SY YFDWQGGTMVTVSS (4) AST KGPS VFPLAPSS KSTS GGTAAL

>p73 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCA GDHWGL YFDLWGRGT LVTVSS (2) AST KGPS VFPLAPSS KSTS GGTAAL

>p96 GISVWRQAPGQGLEWMGWI SAYNGNTN YAQK LQGRVTMT DTS TSTA YMLRSLRSDDTAVVYCA SDHWGL YFDLWGRGT LVTVSS (2) AST KGPS VFPLAPSS KSTS GGTAAL



**Supplementary Fig. 1 | V(D)J sequencing. a,** Graphical representation of a total of 3.95 million read pairs obtained from V(D)J sequencing displayed for each PCR product. Read pairs represent the number of paired end reads obtained from the sequencer. After merging (merged reads), the reads were selected based on the presence of the forward and reverse primer sequences which represent all rearrangements. The number of unique amino acid sequences after translating are depicted as unique rearrangements. These sequences were further filtered for the presence of the primer including 5 expected adjacent amino acids in the correct reading frame and the absence of stop codons to obtain potentially functional rearrangements. The isotype of the potentially functional rearrangements was determined by the presence of the protein tag SSKSTSGG (C $\gamma$ 1) or CSRSTSES (C $\gamma$ 4). In total, C $\gamma$ 4 switch variants are very rare, summing up to an average of 0,76% of all functional transgenic VH gene rearrangements found. **b,** Selection of the most prominent sequences of potentially functional rearrangements of the transgenic human Ig genes found in the transgenic minipigs are shown as amino acid sequences. Rare C $\gamma$ 4 switch variants are also included. The sequence of the transgenic V genes is depicted (in blue) above rearranged sequences, indicating the position of the amino acids corresponding to N(D)N, J and C regions. Where identified, D gene segments are underlined and named right to the sequence. The numbers in parenthesis in VH and Vk sequences indicate the corresponding J element used. Amino acid variants resulting from point mutations are shown in red. The C $\gamma$ 4 region of switch variants is in brown colour. Same V gene sequences of C $\gamma$ 4 switch variants are also often associated with C $\gamma$ 1.



**Supplementary Fig. 2 | Sequence and structural mapping of the different interactions of PD-L1 epitope amino acid side-chains with atezolizumab paratope residues.** **a**, Sequence alignment of PD-L1 orthologs, human, mouse, and pig. Epitope residues are marked with a C (contact residues); an amino acid 1-letter code is marked in red when the contact is occurring exclusively via the side-chain atoms (amino acids with backbone contact only are kept in black). **b-f**, Molecular models of PD-L1 interaction with atezolizumab. Fourteen interacting side-chains show their contact with paratope residues. The corresponding residue position of PD-L1 interacting with atezolizumab is depicted for human (Hu) mouse (Mu) and pig (Pig) amino acids. Pig PD-L1 residues are indicated in the ball and stick mode (orange carbon atoms) and atezolizumab residues are represented in sticks (grey carbon atoms for the heavy variable region and cyan carbon atoms for the light variable region). PD-L1 and atezolizumab VH and VL are numbered consecutively starting from the first N-terminal residue.

**Supplementary Table. 1 | List of Ab compounds.**

Compound tested	Specificity	Clinical immunogenicity	Immunogenicity in hulgG1 tg mouse model*	Cross-reactivity mouse / pig
bevacizumab (Avastin)	VEGF	0,63 %	0/10 (8/10)	no <sup>41</sup> / yes <sup>42</sup>
daratumumab (Darzalex)	CD38	0 %	0/10 (4/10)	no / no
atezolizumab (Tecentriq)	PD-L1	30 %	10/10 (10/10)	yes / yes
cergutuzumab amunaleukin	CEA / IL2R	79 %	7/10 (7/10) <sup>20</sup>	yes (IL2R) / yes (IL2R)

\*Given as the number of ADA-positive mice of 10 mice immunised in each group. Corresponding numbers for wild type mice are in parenthesis. Unpublished data, manuscript in preparation.



**Supplementary Table. 2 | List of primers.**

<b>PCR amplification target</b>	<b>Primer name</b>	<b>Sequence 5'-&gt;3'</b>
IGH- $\gamma$ 1- $\gamma$ 4 (transgene presence)	IGH_F IGH_R	CTGTCCTACAGTCCTCAGGAC GTGGCACTCATTTACCCGGAG
IGK (transgene presence)	IGK_F IGK_R	TTGTGTGCCTGCTGAAT GCCGCGTGTGAGTAGGTATA
BS (transgene presence)	BS_F BS_R	ATGGCCAAGCCTTTGTCTC GGCGAAGAACTCCAGCATGA
IGH- $\gamma$ 1- $\gamma$ 4 (ddPCR)	dIGH_F dIGH_R	CACCCAGTGCGAGACGAC CTCCTCCTCCCTCGCTCT
IGK (ddPCR)	dIGK_F dIGK_R	GCTATGTAGAAGAGGCAGCT ACCACCTTTCCACCATTACAA
GAPDH (ddPCR)	ddGAPDH_F ddGAPDH_R	CTCAACGACCACTTCGTCAA CCCTGTTGCTGTAGCCAAAT
First VH PCR (RNA sequencing)	Vh1-69_L Vh4-59_L Vh3-30_L Vh3-23_L Vh1-18_L Cg1_4-rev_long	TGGCAGCAGCTACAGGTGTC GCTCCCAGATGGGTCCTGT CGTTGCTCTTTTAAGAGGTGTCC GCTATTTTAAAAGGTGTCCAGTGTG CAGCAACAGGTGCCCACT GGTGTGCTGGGCTTGTG
Nested VH CR (RNA sequencing)	VH1-18_A VH1-69_A VH3-23/30_A VH4-59_A Cg1_4-PCR_A	ATGGTATCAGCTGGGTGCGAC AGGCACCTTCAGCAGCTATGC GCAGACTCCGTGAAGGGCCG AAGGGACTGGAGTGGATTGGG AGTAGTCCTTGACCAGGCAGC
VK PCR (RNA sequencing)	Vk1-17_A Vk3-20_A Ck-PCR_A	GCCAGGTGTGACATCCAGATG AGGCACCCTGTCTTTGTCTCC CAGATGGTGCAGCCACAGTTC